This team of researchers has studied the capabilities and properties of the drug NGR-TNF, a fusion of the peptide Cys-Asn-Gly-Arg-Cys-Gly (CNGRCG, denoted as NGR) and the cytokine TNF-α, and the ligand of aminopeptidase N (CD13) of tumor-blood-vessel-positive (+) blood vessels. The gene discussed is TNF; the disease is neoplasm.